146 related articles for article (PubMed ID: 19464399)
1. Novel antibody specificities targeting glycoprotein B of cytomegalovirus identified by molecular library technology.
Axelsson F; Persson J; Moreau E; Côté MH; Lamarre A; Ohlin M
N Biotechnol; 2009 Sep; 25(6):429-36. PubMed ID: 19464399
[TBL] [Abstract][Full Text] [Related]
2. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.
Axelsson F; Adler SP; Lamarre A; Ohlin M
Vaccine; 2007 Dec; 26(1):41-6. PubMed ID: 18063447
[TBL] [Abstract][Full Text] [Related]
3. Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies.
Schrader JW; McLean GR
Immunol Lett; 2007 Sep; 112(1):58-60. PubMed ID: 17714794
[TBL] [Abstract][Full Text] [Related]
4. Non-germ-line encoded residues are critical for effective antibody recognition of a poorly immunogenic neutralization epitope on glycoprotein B of human cytomegalovirus.
Lantto J; Lindroth Y; Ohlin M
Eur J Immunol; 2002 Jun; 32(6):1659-69. PubMed ID: 12115649
[TBL] [Abstract][Full Text] [Related]
5. Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties.
Barrios Y; Knör S; Lantto J; Mach M; Ohlin M
Mol Immunol; 2007 Feb; 44(5):680-90. PubMed ID: 16824601
[TBL] [Abstract][Full Text] [Related]
6. Towards a novel vaccine against human cytomegalovirus based on a chimeric Ad5F35 adenovirus vector expressing the immunodominant antigenic domain 1 epitope.
Zhao P; Ma D; Yan S; Shao N; Zhang J; Bi Z; Dai J; Ji M; Ji C
Intervirology; 2009; 52(1):35-42. PubMed ID: 19372702
[TBL] [Abstract][Full Text] [Related]
7. A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?
Ohlin M
Mol Immunol; 2014 Aug; 60(2):95-102. PubMed ID: 24802891
[TBL] [Abstract][Full Text] [Related]
8. Identification of a conserved linear B-cell epitope at the N-terminus of the E2 glycoprotein of Classical swine fever virus by phage-displayed random peptide library.
Peng WP; Hou Q; Xia ZH; Chen D; Li N; Sun Y; Qiu HJ
Virus Res; 2008 Aug; 135(2):267-72. PubMed ID: 18485511
[TBL] [Abstract][Full Text] [Related]
9. Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B.
Britt WJ; Jarvis MA; Drummond DD; Mach M
J Virol; 2005 Apr; 79(7):4066-79. PubMed ID: 15767408
[TBL] [Abstract][Full Text] [Related]
10. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
Zhang C; Pass RF
Vaccine; 2004 Dec; 23(4):507-10. PubMed ID: 15530699
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus.
Spindler N; Rücker P; Pötzsch S; Diestel U; Sticht H; Martin-Parras L; Winkler TH; Mach M
J Virol; 2013 Aug; 87(16):8927-39. PubMed ID: 23740990
[TBL] [Abstract][Full Text] [Related]
12. Development of a vaccine marker technology: display of B cell epitopes on the surface of recombinant polyomavirus-like pentamers and capsoids induces peptide-specific antibodies in piglets after vaccination.
Neugebauer M; Walders B; Brinkman M; Ruehland C; Schumacher T; Bertling WM; Geuther E; Reiser CO; Reichel C; Strich S; Hess J
Biotechnol J; 2006 Dec; 1(12):1435-46. PubMed ID: 17109492
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.
Finnefrock AC; Freed DC; Tang A; Li F; He X; Wu C; Nahas D; Wang D; Fu TM
Hum Vaccin Immunother; 2016 Aug; 12(8):2106-2112. PubMed ID: 26986197
[TBL] [Abstract][Full Text] [Related]
14. Antibody engineering and modification technologies.
Filpula D
Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
[TBL] [Abstract][Full Text] [Related]
15. In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an "undruggable" class of disease targets.
Visintin M; Melchionna T; Cannistraci I; Cattaneo A
J Biotechnol; 2008 May; 135(1):1-15. PubMed ID: 18395925
[TBL] [Abstract][Full Text] [Related]
16. Comparison of vaccine strategies against congenital CMV infection in the guinea pig model.
Schleiss MR
J Clin Virol; 2008 Mar; 41(3):224-30. PubMed ID: 18060834
[TBL] [Abstract][Full Text] [Related]
17. Characterizing Epitope Binding Regions of Entire Antibody Panels by Combining Experimental and Computational Analysis of Antibody: Antigen Binding Competition.
Brooks BD; Closmore A; Yang J; Holland M; Cairns T; Cohen GH; Bailey-Kellogg C
Molecules; 2020 Aug; 25(16):. PubMed ID: 32796656
[TBL] [Abstract][Full Text] [Related]
18. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 (CBD1) contains several overlapping neutralizing epitopes.
Benferhat R; Krust B; Rey-Cuillé MA; Hovanessian AG
Vaccine; 2009 Jun; 27(27):3620-30. PubMed ID: 19464543
[TBL] [Abstract][Full Text] [Related]
19. Engineered affinity proteins--generation and applications.
Grönwall C; Ståhl S
J Biotechnol; 2009 Mar; 140(3-4):254-69. PubMed ID: 19428722
[TBL] [Abstract][Full Text] [Related]
20. Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis.
Scarselli M; Cantini F; Santini L; Veggi D; Dragonetti S; Donati C; Savino S; Giuliani MM; Comanducci M; Di Marcello F; Romagnoli G; Pizza M; Banci L; Rappuoli R
J Mol Biol; 2009 Feb; 386(1):97-108. PubMed ID: 19100746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
